Tags

Type your tag names separated by a space and hit enter

Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders.
Phytother Res. 2005 Mar; 19(3):183-8.PR

Abstract

INTRODUCTION

The herbal medicinal product kava-kava, used for treating anxiety disorders, was assessed positively by the Cochrane Review. However, it was withdrawn from the market in Switzerland and Germany due to cases of liver failure and 'unproven' efficacy.

METHODS

A protocol for the meta-analysis based on patient source data was written, a literature search was done, and six placebo-controlled, randomized trials with the kava extract WS1490 were identified. The endpoints were the change in HAMA during treatment (continuous and binary).

RESULTS

WS1490 has an effective success rate of OR=3.3 (95% confidence interval of 2.09-5.22) in patients with non-psychotic anxiety disorders. The continuous outcome supports this result: mean improvement with WS1490 by 5.94 (95% confidence interval -0.86 to 12.8) points on the HAMA scale better than placebo. Kava seems to be more effective in females and in younger patients.

DISCUSSION

This meta-analysis has no publication bias, no remarkable heterogeneity and is based on trials with high methodological standards. It is concluded that WS1490, and possibly other kava extracts, are effective. Therefore they remain alternatives to benzodiazepines, selective serotonin re-uptake inhibitors (SSRIs) and other antidepressants in the treatment of non-psychotic anxiety disorders.

Authors+Show Affiliations

University of Heidelberg, Institute of Medical Biometry and Informatics, Im Neuenheimer Feld 305, D-69120 Heidelberg, Germany.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

15934028

Citation

Witte, Steffen, et al. "Meta-analysis of the Efficacy of the Acetonic Kava-kava Extract WS1490 in Patients With Non-psychotic Anxiety Disorders." Phytotherapy Research : PTR, vol. 19, no. 3, 2005, pp. 183-8.
Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res. 2005;19(3):183-8.
Witte, S., Loew, D., & Gaus, W. (2005). Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytotherapy Research : PTR, 19(3), 183-8.
Witte S, Loew D, Gaus W. Meta-analysis of the Efficacy of the Acetonic Kava-kava Extract WS1490 in Patients With Non-psychotic Anxiety Disorders. Phytother Res. 2005;19(3):183-8. PubMed PMID: 15934028.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. AU - Witte,Steffen, AU - Loew,Dieter, AU - Gaus,Wilhelm, PY - 2005/6/4/pubmed PY - 2005/7/22/medline PY - 2005/6/4/entrez SP - 183 EP - 8 JF - Phytotherapy research : PTR JO - Phytother Res VL - 19 IS - 3 N2 - INTRODUCTION: The herbal medicinal product kava-kava, used for treating anxiety disorders, was assessed positively by the Cochrane Review. However, it was withdrawn from the market in Switzerland and Germany due to cases of liver failure and 'unproven' efficacy. METHODS: A protocol for the meta-analysis based on patient source data was written, a literature search was done, and six placebo-controlled, randomized trials with the kava extract WS1490 were identified. The endpoints were the change in HAMA during treatment (continuous and binary). RESULTS: WS1490 has an effective success rate of OR=3.3 (95% confidence interval of 2.09-5.22) in patients with non-psychotic anxiety disorders. The continuous outcome supports this result: mean improvement with WS1490 by 5.94 (95% confidence interval -0.86 to 12.8) points on the HAMA scale better than placebo. Kava seems to be more effective in females and in younger patients. DISCUSSION: This meta-analysis has no publication bias, no remarkable heterogeneity and is based on trials with high methodological standards. It is concluded that WS1490, and possibly other kava extracts, are effective. Therefore they remain alternatives to benzodiazepines, selective serotonin re-uptake inhibitors (SSRIs) and other antidepressants in the treatment of non-psychotic anxiety disorders. SN - 0951-418X UR - https://www.unboundmedicine.com/medline/citation/15934028/Meta_analysis_of_the_efficacy_of_the_acetonic_kava_kava_extract_WS1490_in_patients_with_non_psychotic_anxiety_disorders_ L2 - https://doi.org/10.1002/ptr.1609 DB - PRIME DP - Unbound Medicine ER -